FdaApplication
NDA 217899
Identifiers
- fda_app_no: NDA217899
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2024-08-14 |
Revenue by product
LIVDELZI
| Period | Revenue |
|---|---|
| Q2 2026 | $167.0M |
| Q1 2026 | $133.0M |
| Q2 2025 | $78.0M |
| Q1 2025 | $40.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LIVDELZI | SELADELPAR LYSINE | EQ 10MG BASE | CAPSULE;ORAL |
1 product